Regulus Therapeutics Inc. (RGLS) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Regulus Therapeutics Inc. (RGLS) Bundle
Looking to assess the intrinsic value of Regulus Therapeutics Inc.? Our RGLS DCF Calculator integrates real-world data with extensive customization features, allowing you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.8 | 10.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 46.46 | -100 | 0 | 0 | -13.39 | -13.39 | -13.39 | -13.39 | -13.39 |
| EBITDA | -15.5 | -13.5 | -27.4 | -28.1 | -30.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -227.3 | -134.47 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | .9 | .5 | .5 | .1 | .2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 13.63 | 4.67 | 100 | 100 | 100 | 63.66 | 63.66 | 63.66 | 63.66 | 63.66 |
| EBIT | -16.5 | -13.9 | -27.8 | -28.2 | -31.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -240.93 | -139.14 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | 34.1 | 31.1 | 60.4 | 39.2 | 23.8 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.1 | .5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 16.7 | 5.03 | 100 | 100 | 100 | 64.35 | 64.35 | 64.35 | 64.35 | 64.35 |
| Inventories | 3.9 | 3.3 | .0 | .0 | 3.0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 57.44 | 33.12 | 100 | 100 | 100 | 78.11 | 78.11 | 78.11 | 78.11 | 78.11 |
| Accounts Payable | 1.3 | .5 | .3 | .2 | .2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 19.34 | 5.35 | 100 | 100 | 100 | 64.94 | 64.94 | 64.94 | 64.94 | 64.94 |
| Capital Expenditure | -.2 | .0 | -.3 | -.4 | -.6 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -3.57 | -0.10993 | 100 | 100 | 100 | -0.73627 | -0.73627 | -0.73627 | -0.73627 | -0.73627 |
| Tax Rate, % | -0.00332934 | -0.00332934 | -0.00332934 | -0.00332934 | -0.00332934 | -0.00332934 | -0.00332934 | -0.00332934 | -0.00332934 | -0.00332934 |
| EBITAT | -16.5 | -13.5 | -27.8 | -28.2 | -31.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -19.5 | -12.6 | -24.0 | -28.6 | -34.5 | 2.8 | .0 | .0 | .0 | .0 |
| WACC, % | 13.13 | 13.07 | 13.13 | 13.13 | 13.13 | 13.12 | 13.12 | 13.12 | 13.12 | 13.12 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 2 | |||||||||
| Net Debt | -21 | |||||||||
| Equity Value | 24 | |||||||||
| Diluted Shares Outstanding, MM | 19 | |||||||||
| Equity Value Per Share | 1.26 |
What You Will Get
- Comprehensive RGLS Financials: Access to both historical and projected data for precise valuation.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Automated Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Regulus Therapeutics’ future outlook.
- User-Friendly Design: Designed for industry professionals while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life RGLS Financials: Pre-filled historical and projected data for Regulus Therapeutics Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Regulus’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Regulus’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Model: Download and open the Excel template containing Regulus Therapeutics Inc.'s (RGLS) preloaded data.
- 2. Adjust Key Variables: Modify essential inputs such as projected revenues, discount rates, and research expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes the intrinsic value and net present value.
- 4. Explore Different Scenarios: Evaluate various projections to understand potential valuation impacts.
- 5. Make Informed Decisions: Share expert valuation analyses to guide your strategic choices.
Why Choose This Calculator for Regulus Therapeutics Inc. (RGLS)?
- Designed for Experts: A sophisticated tool tailored for biotech analysts, investors, and financial advisors.
- Comprehensive Data: Regulus Therapeutics' historical and projected financials integrated for reliable insights.
- Flexible Scenario Analysis: Effortlessly model various projections and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a seamless experience.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Regulus Therapeutics Inc. (RGLS) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Regulus Therapeutics Inc. (RGLS).
- Consultants: Deliver professional valuation insights on Regulus Therapeutics Inc. (RGLS) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like Regulus Therapeutics Inc. (RGLS) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Regulus Therapeutics Inc. (RGLS).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Regulus Therapeutics Inc. (RGLS) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Regulus Therapeutics Inc. (RGLS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.